Infigratinib (Truseltiq)

Mechanism of action

From the NCI Drug Dictionary: An orally bioavailable pan inhibitor of human fibroblast growth factor receptors (FGFRs) with potential antiangiogenic and antineoplastic activities. Infigratinib selectively binds to and inhibits the activities of FGFRs, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation, and the induction of tumor cell death.

Diseases for which it is used

• Cholangiocarcinoma

History of changes in FDA indication

• 2021-05-28: Accelerated approval for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. (Based on CBGJ398X2204)

History of changes in Health Canada indication

• 2021-09-27: Initial notice of compliance with conditions for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 fusion or other rearrangement.

Also known as

• Code name: BGJ-398
• Brand name: Truseltiq